Opinion

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work. As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.

In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.

Here in New Jersey, our home base, summer is officially upon us, and the Canadian wildfire smoke has just cleared from the air. I’m sure the bird watchers would attest to the eager chirping as both wildlife and humans greedily enjoy the beautiful weather. But even as the seasons change, so does the technology that drives innovation, as coverage in the July issue of Pharmaceutical Executive® attests.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

This month, we deliver deep dives into the industry's commercial output and outlook and how drugmakers are faring in their public trust mandate—two areas where respective growth pursuits can often go hand-in-hand.

As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.

This year marks my first involvement in Pharmaceutical Executive’s Emerging Pharma Leaders (EPL) Awards, and what a ride it has been. We received so many wonderful nominations, and it’s always humbling to learn about some of the intricacies of the research that’s being done as well as the accomplishments of both current leaders and up-and-coming leaders.

The importance of not over-expanding during development, launch.

The rise of DOLs doesn’t mean pharma should upend KOL approach.

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

Agility and better decisions depend on managing risk and gaining insights from data by prioritizing patient and end-user needs. Companies of all sizes, including GSK, Boehringer-Ingelheim, Sanofi, AstraZeneca, and AbbVie, share best practices.

New regulations may require regulators to explore new payment options.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.

A roadmap for cohering patient perspectives.

Industry must continue research and development to combat the pandemic.

Investments setting up sector for future success that could one day rival its US counterpart.

Approval of Medicare and Medicaid coverage for digital therapeutics represents next step in advancing care for mental health patients.

Rise in demand for sustainable practices forces industry to be more proactive.

Looking to the past reminds industry of great strides taken in clinical research for patients.

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.

How early stage can help set you up for big stage.

Continued push for latest technology in biopharma will advance collection of patient data.

Obstacles in data exchange remain for industry.

As big tech’s healthcare disruption efforts flag, biopharma can step up to empower patients and improve care, writes Rohit Gupta.

AstraZeneca’s Niko Andre discusses the power of patient partnership in driving medical progress.

Recognizing leadership in pharma.

Stay-at-home orders during the pandemic forced a shift in patient preferences—and the pharma industry has responded.